Choreo LLC Buys Shares of 4,047 CRISPR Therapeutics AG (NASDAQ:CRSP)

Choreo LLC bought a new stake in CRISPR Therapeutics AG (NASDAQ:CRSP) during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 4,047 shares of the company’s stock, valued at approximately $218,000.

Several other hedge funds have also recently made changes to their positions in the company. Riggs Asset Managment Co. Inc. raised its stake in shares of CRISPR Therapeutics by 66.7% in the first quarter. Riggs Asset Managment Co. Inc. now owns 500 shares of the company’s stock valued at $34,000 after buying an additional 200 shares during the period. SFE Investment Counsel raised its stake in shares of CRISPR Therapeutics by 3.6% in the second quarter. SFE Investment Counsel now owns 5,846 shares of the company’s stock valued at $316,000 after buying an additional 203 shares during the period. Orion Capital Management LLC raised its stake in shares of CRISPR Therapeutics by 44.0% in the first quarter. Orion Capital Management LLC now owns 720 shares of the company’s stock valued at $49,000 after buying an additional 220 shares during the period. National Bank of Canada FI raised its stake in shares of CRISPR Therapeutics by 35.0% in the second quarter. National Bank of Canada FI now owns 848 shares of the company’s stock valued at $46,000 after buying an additional 220 shares during the period. Finally, Larson Financial Group LLC raised its stake in shares of CRISPR Therapeutics by 95.5% in the second quarter. Larson Financial Group LLC now owns 565 shares of the company’s stock valued at $31,000 after buying an additional 276 shares during the period. 69.20% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

CRSP has been the topic of a number of analyst reports. Truist Financial decreased their price objective on CRISPR Therapeutics from $120.00 to $100.00 and set a “buy” rating on the stock in a research note on Monday, August 12th. StockNews.com upgraded CRISPR Therapeutics to a “sell” rating in a research note on Friday, August 16th. Stifel Nicolaus decreased their price objective on CRISPR Therapeutics from $60.00 to $59.00 and set a “hold” rating on the stock in a research note on Tuesday, August 6th. Royal Bank of Canada decreased their price objective on CRISPR Therapeutics from $66.00 to $60.00 and set a “sector perform” rating on the stock in a research note on Tuesday, August 6th. Finally, Cantor Fitzgerald reiterated a “neutral” rating on shares of CRISPR Therapeutics in a research note on Thursday, August 8th. Three analysts have rated the stock with a sell rating, eight have given a hold rating and nine have given a buy rating to the company. According to data from MarketBeat, CRISPR Therapeutics currently has an average rating of “Hold” and a consensus target price of $75.63.

CRISPR Therapeutics Trading Down 0.2 %

CRSP opened at $49.49 on Friday. The stock has a 50-day moving average price of $50.64 and a 200-day moving average price of $57.40. CRISPR Therapeutics AG has a 12-month low of $37.55 and a 12-month high of $91.10. The stock has a market capitalization of $4.20 billion, a P/E ratio of -18.19 and a beta of 1.68.

CRISPR Therapeutics (NASDAQ:CRSP) last issued its earnings results on Monday, August 5th. The company reported ($1.49) earnings per share for the quarter, missing the consensus estimate of ($1.43) by ($0.06). The company had revenue of $0.52 million during the quarter, compared to the consensus estimate of $12.31 million. CRISPR Therapeutics’s revenue for the quarter was down 99.3% compared to the same quarter last year. During the same period in the previous year, the company earned ($0.98) EPS. On average, equities research analysts predict that CRISPR Therapeutics AG will post -5.6 EPS for the current year.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.